GSK3B and diabetes mellitus: Increased expression of GSK3β has also been observed within podocytes in preclinical rodent models of diabetes (7, 9, 12, 14) and pharmacologic inhibition of GSK3β has shown promise in ameliorating diabetic kidney injury (9, 14, 15, 16, 17, 18, 19).